Compare Carnival Corp (CCL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Mesoblast Limited — how do they compare? Carnival Corp trades at $26.56 (market cap $36.30B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Carnival Corp is far larger — about 17.1× Mesoblast Limited's market cap, and Carnival Corp pays a 1.7% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CCL | MESO | |
|---|---|---|
Market Cap | $36.30B | $2.12B |
Sector | Consumer Cyclical | Technology |
52-Week High | $33.99 | $20.96 |
52-Week Low | $23.89 | $10.96 |
Enterprise Value | $60.22B | $2.13B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.
The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
